Publications by authors named "Jade Clarson"

Claim this Profile
C
CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib.
Chung Hoow Kok, Yazad Irani, Jade Clarson, Verity Saunders, Phuong Dang

Blood Neoplasia· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
Yazad D Irani, Amy Hughes, Chung H Kok, Jade Clarson, David T Yeung

Br J Haematol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.
Yazad D Irani, Chung H Kok, Jade Clarson, Naranie Shanmuganathan, Susan Branford

Blood Adv· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.
Nadia El Khawanky, Amy Hughes, Wenbo Yu, Renier Myburgh, Tony Matschulla, Jade Clarson

Nat Commun· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells.
Yazad D Irani, Amy Hughes, Jade Clarson, Chung H Kok, Naranie Shanmuganathan

Br J Haematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia.
David M Ross, Ilaria S Pagani, Yazad D Irani, Jade Clarson, Tamara Leclercq

Br J Haematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".
Amy Hughes, Jade Clarson, Tessa Gargett, Wenbo Yu, Michael P Brown

Leuk Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Amy Hughes, Jade Clarson, Carine Tang, Ljiljana Vidovic, Deborah L White

Blood· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis